Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha
Yıl: 2018 Cilt: 24 Sayı: 2 Sayfa Aralığı: 25 - 42 Metin Dili: İngilizce DOI: 10.4274/vhd.2017.0016 İndeks Tarihi: 05-02-2019
Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha
Öz: Objectives: It was aimed to evaluate health-related quality of lifeof patients with non-cirrhotic chronic hepatitis B (CHB) and chronichepatitis C (CHC) during interferon therapy with the standard shortform-36 (SF-36).Materials and Methods: This study included all patients whoattended the Atatürk University Faculty of Medicine, Department ofInfectious Diseases and Clinical Microbiology and outpatient clinicsfor treatment between June 2008 and June 2010 and met theinclusion criteria. A socio-demographic data questionnaire and SF36were administered in all subjects before the interferon therapyand in the third and sixth months of the treatment.Results: Before the treatment, vitality/energy (p=0.01) and generalhealth (p=0.01) scores in patients with CHB were lower than incontrols. In the sixth month of the therapy, physical function (p=0.03),role physical (p=0.011), role emotional (p=0.003) and vitality/energy(p=0.005) scores were significantly lower than in controls. There wasa significant difference in physical function (p=0.006), role physical(p=0.006), role emotional (p=0.001) and vitality/energy (p=0.000005)scores before the treatment and physical function (p=0.006),role physical (p=0.013), role emotional (p=0.001), vitality/energy(p=0.000005) and mental health (p=0.041) scores in the third monthof the treatment and physical function (p=0.000008), social function(p=0.005), role physical (p=0.0000008), role emotional (p=0.000007),mental health (p=0.001) and vitality/energy (p=0.000005) scores in thesixth month of the treatment between patients with CHC and controls.Conclusion: Providing guidance and counseling to patients withCHB and CHC about their illness and side effects of the drugs willincrease health-related quality of life of patients and will adapt themto their treatment.
Anahtar Kelime: Konular:
Kronik Hepatit B ve Hepatit C’de Pegile İnterferon-alfa Tedavisi Alan Hastalarda Yaşam Kalitesinin Değerlendirilmesi
Öz: Amaç: Non-sirotik kronik hepatit B (KHB) ve kronik hepatit C’li (KHC) hastalarda interferon tedavisi süresince kısa form 36 (SF-36) standart formunu kullanarak sağlıkla ilgili yaşam kalitesini değerlendirmek amaçlanmıştır. Gereç ve Yöntemler: Çalışmaya Haziran 2008 - Haziran 2010 tarihleri tarihleri arasındaki 2 yıllık süre boyunca Atatürk Üniversitesi Tıp Fakültesi, Enfeksiyon Hastlıkları ve Klinik Mikrobiyoloji Anabilim Dalı’na ve polikliniğine başvuran ve çalışmaya dahil edilme kriterlerini karşılayan olgular alındı. Çalışmaya dahil edilen tüm olgulara, interferon tedavisi öncesinde, tedavinin üçüncü ayında ve tedavinin altıncı ayında, sosyo-demografik veri formu ve SF-36 ölçeği uygulandı. Bulgular: KHB’li hastaların tedavi öncesi enerji (p=0,01) ve genel sağlık (p=0,01) skorlarını; tedavinin altıncı ayında fiziksel fonksiyon (p=0,03), fiziksel rol (p=0,011), emosyonel rol (p=0,003) ve enerji (p=0,005) skorlarını kontrol grubuna göre anlamlı düzeyde daha düşüktü. KHC’li hastaların tedavi öncesi fiziksel fonksiyon (p=0,006), fiziksel rol (p=0,006), emosyonel rol (p=0,001) ve enerji (p=0,000005) skorlarında; tedavinin üçüncü ayında fiziksel fonksiyon (p=0,006), fiziksel rol (p=0,013), emosyonel rol (p=0,001), mental sağlık (p=0,041) ve enerji (p=0,000005) skorlarında; tedavinin altıncı ayında ise fiziksel fonksiyon (p=0,000008), sosyal fonksiyon (p=0,005), fiziksel rol (p=0,0000008), emosyonel rol (p=0,000007), mental sağlık (p=0,001) ve enerji (p=0,000005) skorlarında kontrol grubuna göre anlamlı düzeyde farklı olduğu saptanmıştır. Sonuç: Hastalara hastalıkları ve ilaçların yan etkileriyle ilgili rehberlik ve danışmanlık hizmetlerinin verilmesi hastaların yaşam kalitelerini artırıp, tedavi uyumunu sağlayacaktır. Anahtar Kelimeler: Kronik hepatit B, kronik hepatit C, sağlıkla ilgili yaşam kalitesi, interferon tedavisi.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997;26(3 Suppl 1):34-38.
- Özdemir D, Kurt H. Hepatit B virusu İnfeksiyonlarının epidemiyolojisi. Tabak F, Balık İ, Tekeli E, eds. Viral Hepatit 2007.İstanbul, Viral Hepatitle Savaşım Derneği, Oban Matbaası. 2007;108-117.
- Quer J, Esteban J. Epidemiology. In: Thomas HC, Lemon S, Zuckerman AJ eds. Viral hepatitis. Massachusetts, USA. Third Edition. Blackwell Publishing, 2005;407-425.
- Çaylan R. Kronik hepatitler ve yaşam kalitesi. Tabak F, Balık İ, Tekeli E, eds. Viral Hepatit. İstanbul Viral Hepatitle Savaşım Derneği, Oban Matbaası. 2007;376-384.
- Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL. Healthrelated quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology. 1999;30:550-555.
- Mathew A, Peiffer LP, Rhoades K, McGarrity TJ. Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin. Health Qual Life Outcomes. 2006;4:30.
- Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
- Koçyiğit H, Aydemir Ö, Fişek G, Ölmez N, Memiş A. Kısa Form-36 (KF-36)’nın Türkçe İçin Güvenilirliği ve Geçerliliği: Romatizmal Hastalığı Olan Bir Grup Hasta İle Çalışma. İlaç ve Tedavi Dergisi 1999;12:102-105. https://www.researchgate. net/publication/301799662_Kisa_Form-36_SF-36’nin_Turkce_ Versiyonunun_Guvenilirligi_ve_Gecerliligi_Reliability_and_Validity_ of_the_Turkish_Version_of_Short_Form-36_SF-36
- Koçyiğit H, Aydemir Ö, Ölmez N, Fişek G, Ölmez N, Memiş A. Kısa Form-36 (SF-36)’nın Türkçe Versiyonunun Güvenilirliği ve Geçerliliği. İlaç ve Tedavi Dergisi. 1999;12:102-106.
- Aydemir Ö, Köroğlu E. Psikiyatride Kullanılan Klinik Ölçekler. Hekimler Yayın Birliği Ankara 2006;346-353.
- Lam ET, Lam CL, Lai CL, Yuen MF, Fong DY, So TM. Healthrelated quality of life of Southern Chinese with chronic hepatitis B infection. Health Qual Life Outcomes. 2009;7:52.
- Bondini S, Kallman J, Dan A, Younoszai Z, Ramsey L, Nader F, Younossi ZM. Health-related quality of life in patients with chronic hepatitis B. Liver Int. 2007;27:1119-1125.
- Ozkan M, Corapçioglu A, Balcioglu I, Ertekin E, Khan S, Ozdemir S, Karayün D, Unsalver BO, Kocaman N, Kaymakglu S, Köroglu G. Psychiatric morbidity and its effect on the quality of life of patients with chronic hepatitis B and hepatitis C. Int J Psychiatry Med. 2006;36:283-297.
- Fontana RJ, Moyer CA, Sonnad S, Lok ASF, Sneed-Pee N, Walsh J, Klein S, Webster S. Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol. 2001;96:170-178.
- Teixeira MC, Ribeiro Mde F, Gayotto LC, Chamone Dde A, Strauss E. Worse quality of life in volunteer blood donors with hepatitis C. Transfusion. 2006;46:278-283.
- Olson SH, Iyer S, Scott J, Erez O, Samuel S, Markovits T, Schwartz M, Toro C, Gambarin-Gelwan M, Kurtz RC. Cancer history and other personal factors affect quality of life in patients with hepatitis C. Health Qual Life Outcomes. 2005;3:39.
- Eşer İ, Khorshid L, Türk G. Kronik Hepatit C Hastalarının Sağlıkla İlişkili Yaşam Kalitesinin Değerlendirilmesi. Viral Hepat J. 2006;11:41-45.
- Kallman J, O’Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci. 2007;52:2531-2539
- Braga SF, Peixoto SV, Gomes IC, Acúrcio Fde A, Andrade EI, Cherchiglia ML. Factors associated with health-related quality of life in elderly patients on hemodialysis. Rev Saude Publica. 2011;45:1127-1136.
- Gao F, Gao R, Li G, Shang ZM, Hao JY. Health-related quality of life and survival in Chinese patients with chronic liver disease. Health Qual Life Outcomes. 2013;11:131.
- Vlassoff C. Gender differences in determinants and consequences of health and illness. J Health Popul Nutr. 2007;25:47-61.
- Hussain KB, Fontana RJ, Moyer CA, Su GL, Sneed-Pee N, Lok AS. Comorbid illness is an important determinant of healthrelated quality of life in patients with chronic hepatitis C. Am J Gastroenterol. 2001;96:2737-2744.
- Gjeruldsen S, Loge JH, Myrvang B, Opjordsmoen S. Drug addiction in hepatitis C patients leads to a lower quality of life. Nord J Psychiatry. 2006;60:157-161.
- Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41:790-800.
- Kang SC, Hwang SJ, Lee SH, Chang FY, Lee SD. Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World J Gastroenterol. 2005;11:7494-7498.
- Gallegos-Orozco JF, Fuentes AP, Gerardo Argueta J, Pérez-Pruna C, Hinojosa-Becerril C, Sixtos-Alonso MS, Cruz-Castellanos S, Gutiérrez-Reyes G, Olivera-Martínez MA, Gutiérrez-Ruiz MC, Kershenobich D. Health-related quality of life and depression in patients with chronic hepatitis C. Arch Med Res. 2003;34:124- 129.
- Pojoga C, Dumitraşcu DL, Pascu O, Grigorescu M, Radu C, Damian D. Impaired health-related quality of life in Romanian patients with chronic viral hepatitis before antiviral therapy. Eur J Gastroenterol Hepatol. 2004;16:27-31.
- Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology. 2002;35:704-708.
- McHutchison JG, Ware JE Jr, Bayliss MS, Pianko S, Albrecht JK, Cort S, Yang I, Neary MP; Hepatitis Interventional Therapy Group. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol. 2001;34:140-147.
- Marcellin P, Lau GK, Zeuzem S, Heathcote EJ, Pockros PJ, Reddy KR, Piratvisuth T, Farci P, Chow WC, Jia JD, Paik W, Wintfeld N, Pluck N. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int. 2008;28:477-485.
| APA | ALAY H, OZDEN K, EROL S, Çelik N, PARLAK E, Parlak M (2018). Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha. , 25 - 42. 10.4274/vhd.2017.0016 |
| Chicago | ALAY HANDAN,OZDEN KEMALETTIN,EROL Serpil,Çelik Neslihan,PARLAK Emine,Parlak Mehmet Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha. (2018): 25 - 42. 10.4274/vhd.2017.0016 |
| MLA | ALAY HANDAN,OZDEN KEMALETTIN,EROL Serpil,Çelik Neslihan,PARLAK Emine,Parlak Mehmet Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha. , 2018, ss.25 - 42. 10.4274/vhd.2017.0016 |
| AMA | ALAY H,OZDEN K,EROL S,Çelik N,PARLAK E,Parlak M Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha. . 2018; 25 - 42. 10.4274/vhd.2017.0016 |
| Vancouver | ALAY H,OZDEN K,EROL S,Çelik N,PARLAK E,Parlak M Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha. . 2018; 25 - 42. 10.4274/vhd.2017.0016 |
| IEEE | ALAY H,OZDEN K,EROL S,Çelik N,PARLAK E,Parlak M "Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha." , ss.25 - 42, 2018. 10.4274/vhd.2017.0016 |
| ISNAD | ALAY, HANDAN vd. "Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha". (2018), 25-42. https://doi.org/10.4274/vhd.2017.0016 |
| APA | ALAY H, OZDEN K, EROL S, Çelik N, PARLAK E, Parlak M (2018). Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha. Viral Hepatitis Journal, 24(2), 25 - 42. 10.4274/vhd.2017.0016 |
| Chicago | ALAY HANDAN,OZDEN KEMALETTIN,EROL Serpil,Çelik Neslihan,PARLAK Emine,Parlak Mehmet Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha. Viral Hepatitis Journal 24, no.2 (2018): 25 - 42. 10.4274/vhd.2017.0016 |
| MLA | ALAY HANDAN,OZDEN KEMALETTIN,EROL Serpil,Çelik Neslihan,PARLAK Emine,Parlak Mehmet Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha. Viral Hepatitis Journal, vol.24, no.2, 2018, ss.25 - 42. 10.4274/vhd.2017.0016 |
| AMA | ALAY H,OZDEN K,EROL S,Çelik N,PARLAK E,Parlak M Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha. Viral Hepatitis Journal. 2018; 24(2): 25 - 42. 10.4274/vhd.2017.0016 |
| Vancouver | ALAY H,OZDEN K,EROL S,Çelik N,PARLAK E,Parlak M Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha. Viral Hepatitis Journal. 2018; 24(2): 25 - 42. 10.4274/vhd.2017.0016 |
| IEEE | ALAY H,OZDEN K,EROL S,Çelik N,PARLAK E,Parlak M "Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha." Viral Hepatitis Journal, 24, ss.25 - 42, 2018. 10.4274/vhd.2017.0016 |
| ISNAD | ALAY, HANDAN vd. "Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha". Viral Hepatitis Journal 24/2 (2018), 25-42. https://doi.org/10.4274/vhd.2017.0016 |
